Compare DexCom, Inc. (DXCM) vs Macy's Inc (M) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Macy's (M) trades at $24.04, up 3.55% today, with a bullish technical signal and positive earnings momentum after beating estimates in three consecutive quarters. The stock shows attractive valuation metrics with a P/E of 9.82 and P/S of 0.29, while recent news highlights strategic initiatives including AI integration and leadership appointments. Cash flow trends improved in 2025 with net cash flow of $273 million, though revenue declined slightly to $23.01 billion.

Outlook remains cautiously optimistic with a consensus price target of $24.83 offering modest upside. Key opportunities include operational efficiency gains and luxury segment growth, while risks involve competitive retail pressures and macroeconomic sensitivity. Institutional interest is growing with Berkshire Hathaway's recent 3 million share purchase (Barron's, June 22, 2026).